Twin Lakes Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Twin Lakes Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98.6K	Hold	158	–	–	0.04%	104
2026 Q1	$122K	Sell	158 -107	-40%	-$81.9K	0.06%	99
2025 Q4	$205K	Hold	265	–	–	0.09%	84
2025 Q3	$149K	Sell	265 -2	-0.7%	-$1.13K	0.07%	92
2025 Q2	$140K	Buy	267 +1	+0.4%	+$558	0.09%	88
2025 Q1	$169K	Hold	266	–	–	0.11%	86
2024 Q4	$189K	Hold	266	–	–	0.12%	87
2024 Q3	$280K	Hold	266	–	–	0.18%	73
2024 Q2	$280K	Hold	266	–	–	0.19%	69
2024 Q1	$256K	Hold	266	–	–	0.17%	74
2023 Q4	$234K	Hold	266	–	–	0.16%	77
2023 Q3	$219K	Hold	266	–	–	0.16%	74
2023 Q2	$191K	Sell	266 -25	-9%	-$19.3K	0.14%	84
2023 Q1	$239K	Hold	291	–	–	0.18%	74
2022 Q4	$210K	Hold	291	–	–	0.16%	77
2022 Q3	$200K	Hold	291	–	–	0.16%	83
2022 Q2	$172K	Hold	291	–	–	0.12%	74
2022 Q1	$203K	Buy	291 +15	+5%	+$9.49K	0.11%	93
2021 Q4	$174K	Sell	276 -14	-5%	-$8.61K	0.09%	105
2021 Q3	$176K	Sell	290 -37	-11%	-$23K	0.1%	96
2021 Q2	$183K	Sell	327 -67	-17%	-$33.9K	0.1%	86
2021 Q1	$186K	Buy	+394	New	+$192K	0.11%	81

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Twin Lakes Capital Management's REGN Position: Q2 2026 in Review

Twin Lakes Capital Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 158 shares worth $98.6K. The position accounts for 0.04% of the portfolio, ranked #104.

Twin Lakes Capital Management first reported a position in REGN in Q1 2021 and has held it in 22 quarters since. The position peaked at $280K in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Twin Lakes Capital Management held 158 shares of Regeneron Pharmaceuticals worth $98.6K as of Q2 2026.
Twin Lakes Capital Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.04% of Twin Lakes Capital Management's portfolio in Q2 2026, its #104 holding.
Twin Lakes Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
Twin Lakes Capital Management's Regeneron Pharmaceuticals position peaked at $280K in Q3 2024.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Twin Lakes Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.